Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 20%GRADE not reported 0 · 0%Very low 1 · 20%Low 3 · 60%Moderate 0 · 0%High 0 · 0%

Postoperative MMC‐EMDA with sequential BCG induction and maintenance vs postoperative BCG induction and maintenance therapy

Time to recurrence

Postoperative MMC‐EMDA with sequential BCG induction and maintenance may leads to lower time to recurrence compared with postoperative BCG induction and maintenance therapy (low certainty).

1 finding from 1 review

Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
HR 0.51 [0.34, 0.77]
1 study · 212 participants
Low

Postoperative MMC‐EMDA with sequential BCG induction and maintenance vs postoperative BCG induction and maintenance therapy

Time to progression

Postoperative MMC‐EMDA with sequential BCG induction and maintenance may leads to lower time to progression compared with postoperative BCG induction and maintenance therapy (low certainty).

1 finding from 1 review

Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
HR 0.36 [0.17, 0.75]
1 study · 212 participants
Low

Postoperative MMC‐EMDA with sequential BCG induction and maintenance vs postoperative BCG induction and maintenance therapy

Serious adverse events

It is very uncertain whether postoperative MMC‐EMDA with sequential BCG induction and maintenance changes serious adverse events compared with postoperative BCG induction and maintenance therapy (very low certainty).

1 finding from 1 review

Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
RR 1.02 [0.21, 4.94]
1 study · 212 participants
Very low

Postoperative MMC‐EMDA with sequential BCG induction and maintenance vs postoperative BCG induction and maintenance therapy

Disease‐specific survival

Postoperative MMC‐EMDA with sequential BCG induction and maintenance may leads to lower disease‐specific survival compared with postoperative BCG induction and maintenance therapy (low certainty).

1 finding from 1 review

Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
HR 0.31 [0.12, 0.8]
1 study · 212 participants
Low

Postoperative MMC‐EMDA with sequential BCG induction and maintenance vs postoperative BCG induction and maintenance therapy

Disease‐specific quality of life ‐ not reported

The review found no eligible studies for this question.

1 finding from 1 review

Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found